Document is current
Any future updates will be listed below
-
Authors
Husain-Syed, Faeq
Takeuchi, Tomonori
Neyra, Javier A.
RamÃrez-Guerrero, Gonzalo
Rosner, Mitchell H.
Ronco, Claudio
Tolwani, Ashita J.
- License Information
-
More Information
Article History
Received: 18 April 2023
Accepted: 30 August 2023
First Online: 3 September 2023
Declarations
:
: Not applicable.
: Not applicable.
: JAN reports consultancy agreements with Baxter Healthcare, Outset Medical, Vifor Pharma, and Leadiant Biosciences, all unrelated to this work. AT reports consultancy for Baxter, receiving honoraria from UptoDate, having a patent on 0.5% trisodium citrate solution for CRRT anti- coagulation, the license for which has been bought by Baxter, and serving on a speakers bureau for Baxter, all unrelated to this work. MHR has received consultant fees from Baxter Healthcare, serves as on the Data Safety Monitoring Boards of clinical trials sponsored by Reata, Travere and Astra Zeneca, all unrelated to this work. CR has received funding for lectures been consultant or advisory board member for Asahi, Astute, B. Braun, Baxter, bioMérieux, Bioporto, CytoSorbents, Estor, Fresenius Medical Care, General Electric (GE), Jafron, Medtronic, Toray. FH-S, TT, and GR-G declare no competing interests.
